# Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban

> **NCT04169269** · PHASE4 · UNKNOWN · sponsor: **Florida Orthopaedic Institute** · enrollment: 128 (estimated)

## Conditions studied

- Deep Vein Thrombosis
- Venous Thromboembolism

## Interventions

- **DRUG:** Enoxaparin 40 milligram/0.4 milliliter Injectable Syringe 0.4 milliliters
- **DRUG:** Rivaroxaban 10 milligram Oral Tablet

## Key facts

- **NCT ID:** NCT04169269
- **Lead sponsor:** Florida Orthopaedic Institute
- **Sponsor class:** NETWORK
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-13
- **Primary completion:** 2020-12
- **Final completion:** 2021-12
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2020-01-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04169269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04169269, "Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04169269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*